Mary K. Caffrey, from AJMC.com

Mark C. Capone discusses the challenges and opportunities in molecular diagnostics, and what's ahead at Myriad Genetics.

The discount drug program intended for safety-net hospitals and special AIDS clinics has mushroomed even more than earlier reports have suggested, with oncology drugs fueling much of the growth, according to a new report commissioned by community oncology providers.

The sheer number of survivors- nearly 15 million in the United States, or 4% of the population-has brought greater attention to ensuring that cancer treatment does not cause other harms, since cancer patients are not only living but also living longer.